MeFirst: A Tailored Intervention to HPV Vaccine Decision Making

Not Applicable

Completed

• Conditions: Human Papillomavirus-Related Carcinoma
• Interventions: Behavioral: MeFirst Tailored Intervention

• Registration Number: NCT01769560
• Lead Sponsor: University of Michigan

Brief Summary

This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.

Detailed Description

MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2013-01
• Study First Submitted: 2013-01-14
• Study First Submitted QC: 2013-01-14
• Study First Posted: 2013-01-16
• Primary Completion: 2014-04
• Study Completion: 2014-04
• Status Verified: 2015-07
• Last Update Submitted: 2015-07-21
• Last Update Posted: 2015-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 661

Inclusion Criteria

• enrolled at the University of Michigan

Read More

Exclusion Criteria

• receipt of any doses of HPV vaccine

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MeFirst Intervention	MeFirst Tailored Intervention	Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.

Primary Outcome Measures

Name	Time	Method
Determine the effect of the MeFirst tool, a tailored, online HPV vaccination decision-making guide, on HPV vaccination intention and/or uptake.	Immediately post intervention, 3 months and 12 months	Intention will be assessed on a five-point scale immediately after and at 3 and 12 months. Uptake will be assessed by yes/no/don't know response to the statement, "I have received at least 1 dose of the HPV vaccine" at 3 and 12 months.

Secondary Outcome Measures

Name	Time	Method
Determine the effect of the MeFirst tool on HPV-related knowledge.	Immediately post intervention, 3 months and 12 months	Comparing 5 or 10-point scales measuring participants' HPV-related knowledge (HPV, HPV vaccination, and cervical cancer) immediately post-intervention and at 3 months and 12 months.

Trial Locations

Locations (1)

Univeristy of Michigan; 🇺🇸 Ann Arbor, Michigan, United States